LAS VEGAS—Skinvisible Inc. entered into a R&D agreement with Women's Choice Pharmaceuticals LLC, a specialty pharmaceutical company based in Gilbert, Ariz. The agreement is to develop a pregascription formulation using Skinvisible's technology Invisicare®, a patented polymer delivery system for topical dermatology and consumer goods products.
Under the terms of the agreement, Skinvisible received a fee for the development of the product. Upon the successful completion, Skinvisible and Women's Choice will enter into a license agreement which includes a license fee paid in milestones plus on-going royalties based on product sales. Development is expected to be completed in the second quarter in anticipation of a third quarter launch.
"We feel Women's Choice will be an important licensee for us as we explore other product development opportunities with them that fit with their strategy and expertise in women's health as well as dermatology,” said Terry Howlett, president and CEO, Skinvisible.